Strongbridge Makes Case For Recorlev In First-Line Cushing's Disease

Recorlev (levoketoconazole) demonstrates efficacy and liver safety in a Phase III single-arm study, but needs to live down the bad rap of ketoconazole and ultimately escape a black box warning.